The laboratory of Scott Lokey uses a small molecule approach, called chemical genetics, to study signaling pathways related to cell cycle checkpoints and the actin cytoskeleton. In one study, Lokey and his co-workers are developing screens of natural compounds that can be used to examine how cells detect their own DNA damage. Studies such as these might lead to development of a new class of chemotherapeutic agents.
Similar users
